SCHEMBL4411677

SCHEMBL4411677

CCOP(=O)(OCC)c1cccc(CCc2cccc(P(=O)(OCC)OCC)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.41
ACHE P22303 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2B P41595 1/20 0.41
LTA4H P09960 1/20 0.41
EPHX2 P34913 1/20 0.41
CCNT1 O60563 2/20 0.39
CDK9 P50750 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
AOX1 Q06278 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12229723 0.93 NPSR1 (0.45) NPSR1MEN1KMT2APOLBACHE
SCHEMBL12229683 0.89 POLB (0.53) NPSR1MEN1KMT2APOLBACHE
SCHEMBL7189809 0.88 NPSR1 (0.41) NPSR1MEN1KMT2APOLBACHE
SCHEMBL12229697 0.86 NPSR1 (0.45) NPSR1MEN1KMT2APOLBACHE
SCHEMBL8116136 0.84 LTA4H (0.42) NPSR1MEN1KMT2APOLBLTA4H
SCHEMBL4411675 0.83 NPSR1 (0.36) NPSR1MEN1KMT2AACHEAOX1
SCHEMBL9849259 0.83 NPC1 (0.45) MEN1KMT2ALTA4HEPHX2CA12
SCHEMBL9849286 0.83 LMNA (0.42) NPSR1MEN1KMT2APOLBHTR2A
SCHEMBL14809313 0.82 MEN1 (0.48) NPSR1MEN1KMT2APOLBACHE
SCHEMBL12229745 0.82 MEN1 (0.48) NPSR1MEN1KMT2AACHELTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
EP-1109545-A4 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2004-11-10 EP disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed
EP-1109545-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LTD (AU) 2001-06-27 EP disclosed
WO-2000015214-A1 Fc RECEPTOR MODULATORS AND USES THEREOF ILEXUS PTY LIMITED (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 NPSR1 319/4885MEN1 4070/4885KMT2A 2002/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A NPSR1 257/4885MEN1 3751/4885KMT2A 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.